Premium
First‐line treatments for hepatitis C
Author(s) -
Messori A.,
Del Santo F.,
Maratea D.
Publication year - 2011
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2011.04672.x
Subject(s) - boceprevir , telaprevir , ribavirin , medicine , confidence interval , hepatitis c , clinical trial , interferon , virology , gastroenterology , chronic hepatitis , virus
another died after 12 years. All were on continuous anticoagulation therapy. Among eight patients with EHPVT and MPD (5 male, mean age 55 years), five had ET, two had PMF and one had PRV. On admission, all had signs of portal hypertension and five experienced superior mesenteric vein thrombosis. They are all alive after a mean period of 1.8 years (range, 0.2–6 years) of observation. All patients have been receiving continuous anticoagulation therapy. Non-cirrhotic portal hypertension is an under-recognised entity that closely mimics cirrhosis and needs a strong index of suspicion for the diagnosis. JAK2V617F mutation is found in nearly all cases of PRV and about half the cases of ET and PMF. However, JAK2V617F was present in all patients assessed for the mutation, including those with ET and PMF, a finding reported recently also by other investigators. The ubiquitous presence of JAK2V617F may express a more aggressive phenotype with an increased risk of thrombosis at these distinct sites. In conclusion, JAK2V617F assessment has a unique role in early diagnosis and consequently management of myeloproliferative disorders in the presence of splanchnic vein thrombosis.